q-bio.BMOct 23, 2026

Computational De Novo Design of Miniprotein Candidate Neutralizers Targeting the IL-23 Cytokine Subunit p19

Authors: Raghav Paladugu, Fardina Fathmiul Alam

Organizations: Department of Computer Science, University of Maryland, College Park, MD, USA

Abstract

Interleukin-23 (IL-23) drives T-helper-17 inflammation underlying inflammatory bowel disease and psoriasis; anti-p19 antibodies are clinically effective but large, costly, and injectable. De novo miniproteins are an attractive alternative, yet published designs target the IL-23 receptor; the IL-23 cytokine itself has not been addressed. A further obstacle is that the standard confidence score (ipTM) tracks construct length rather than interface quality. We computationally design miniprotein binders against the IL-23R-binding face of p19 (PDB 3DUH) and score every design with ipSAE, a length-robust interface metric derived from AlphaFold-initial-guess predicted aligned error. A conventional RFdiffusion/ProteinMPNN/ColabFold pipeline yields no reliable predicted interface across 972 designs (best ipSAE 0.30), and a scoring artifact, in which single-sequence ColabFold under-rates binder pLDDT by approximately 56 points, explains an earlier misleading "binders do not fold" signal. An interface-optimized hallucination method (BindCraft), scored identically, yields 42 of 50 designs above ipSAE 0.60 (best 0.804). An AlphaFold-independent geometric check reproduces the conventional failure: no top-ranked conventional design reaches the buried area or interface hydrogen-bond count of the weakest lead. Five all-alpha-helical leads (72-104 residues) collectively engage all six targeted hotspots; two dock within the intact p40/p19 heterodimer and all show favorable Rosetta energetics. A p40-alone counter-screen returns ipSAE 0.00 for all five, indicating no spurious p40 interface. To our knowledge, these are the first computationally proposed de novo miniprotein candidates designed to occlude the IL-23R-binding face of IL-23 p19. All results require experimental validation.

Figures & tables

Explore similar work

Aug 21, 2026

Natural-Language-Guided Generator-Agnostic Shortlisting for Protein Binder Design

Modern de novo design workflows generate many candidate protein binders, but wet-lab validation capacity remains limited, making shortlisting a major bottleneck. We study whether LLMs can generate multi-metric ranking policies from precomputed structural-confidence and interface-quality proxy scores. Rather than proposing a new protein binder design pipeline, we focus on post-generation binder shortlisting: selecting the final top-K candidates from already generated binder pools using a shared panel of precomputed proxy scores. On the 10-target held-out split, averaging performance over five sampled global iterative gpt-4o policies reaches 0.589 Recall@10, modestly improving over the strongest single-feature fixed baseline, Protenix binder ipTM, which reaches 0.571 Recall@10. On the 3-target held-out subset comprising Nipah, RBX1, and TREM2, target-conditioned iterative gpt-5.4 policies reach the strongest LLM performance, with 0.519 Recall@10 and 0.583 NDCG@10. These results suggest that LLM-generated ranking policies can act as an interpretable post-generation decision layer for combining heterogeneous proxy metrics to prioritize binders from large candidate pools.
Mar 30, 2026

Scaling Atomistic Protein Binder Design with Generative Pretraining and Test-Time Compute

Protein interaction modeling is central to protein design, which has been transformed by machine learning with applications in drug discovery and beyond. In this landscape, structure-based de novo binder design is cast as either conditional generative modeling or sequence optimization via structure predictors ("hallucination"). We argue that this is a false dichotomy and propose Proteina-Complexa, a novel fully atomistic binder generation method unifying both paradigms. We extend recent flow-based latent protein generation architectures and leverage the domain-domain interactions of monomeric computationally predicted protein structures to construct Teddymer, a new large-scale dataset of synthetic binder-target pairs for pretraining. Combined with high-quality experimental multimers, this enables training a strong base model. We then perform inference-time optimization with this generative prior, unifying the strengths of previously distinct generative and hallucination methods. Proteina-Complexa sets a new state of the art in computational binder design benchmarks: it delivers markedly higher in-silico success rates than existing generative approaches, and our novel test-time optimization strategies greatly outperform previous hallucination methods under normalized compute budgets. We also demonstrate interface hydrogen bond optimization, fold class-guided binder generation, and extensions to small molecule targets and enzyme design tasks, again surpassing prior methods. Code, models and new data will be publicly released.
Oct 10, 2026

Joint Discrete and SE(3) Diffusion for Protein Interface Design

The design of high-affinity, target-specific protein binders is central to the development of modern therapeutics. However, existing protein-generation methods remain limited in this setting, as many generated designs fail to simultaneously achieve geometric and physicochemical complementarity at binding interfaces. To address this challenge, we introduce PIDiff, a physicochemically enhanced multimodal diffusion framework for protein-protein complex design. PIDiff jointly designs target-conditioned protein sequences and structures by coupling diffusion in discrete sequence space with diffusion on the continuous (SE(3)) structural manifold. At its core, PIDiff employs PIFormer, a novel architecture that interleaves geometry-aware invariant point attention with global sequence self-attention. We further curate PIBench, a protein-protein complex dataset with diverse target scaffolds derived from the Protein Data Bank (PDB). We first pretrain PIDiff on PIBench and subsequently fine-tune it for two therapeutically relevant applications: minibinder design and antibody design. PPFrame consistently outperforms baseline methods across sequence design success rate, structure binding energy, and sequence-structure co-designability on all tasks.